chartexchange

NRIX Slumps 35% After-Hours — What’s Driving The Selloff?

Stocktwits | Nov 3, 2026 5:58 PM EST

Sanofi notified Nurix that it is ending the early-stage first-in-human trial of SAR448272 and terminating the program entirely.

Read original article